|
시장보고서
상품코드
2050978
겸상 적혈구 증후군 치료 시장 : 치료법별, 연령층별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별Sickle Cell Disease Treatment Market, By Treatment Type, By Age Group, By Route of Administration, By End User, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
겸상 적혈구 증후군 치료 시장은 2026년에 37억 달러로 추정되며, 2033년까지 103억 5,000만 달러에 이를 전망입니다. 또한 2026-2033년 CAGR 15.8%를 나타낼 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 37억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 15.80% | 2033년 시장 규모 예측 : | 103억 5,000만 달러 |
겸상 적혈구 증후군은 적혈구의 이상을 일으키는 유전성 혈액질환입니다. 이 질환은 체내 조직과 장기에 산소 공급에 영향을 미칩니다. 이 질병은 전 세계적으로 널리 퍼져 있으며, 특히 사하라 이남 아프리카, 중동, 인도 아대륙, 지중해 지역, 남미에서 많이 발생합니다. 진단 및 검출률의 향상과 더불어 첨단 치료 옵션에 대한 인식이 높아짐에 따라 향후 몇 년 동안 시장은 큰 성장 기회를 보일 것으로 예측됩니다. 또한, 신약요법 및 유전자치료에 기반한 치료법 개발도 시장 확대에 힘을 보태고 있습니다.
시장 역학
신약 개발 및 향후 파이프라인 후보물질에 초점을 맞춘 연구 활동 증가는 세계 겸상 적혈구 증후군 치료제 시장의 주요 성장 요인으로 작용하고 있습니다. 신흥국의 의료비 지출 증가 및 유리한 상환 정책도 시장 성장을 더욱 촉진하고 있습니다. 골수이식 등 근본적인 치료법의 채택 확대도 시장을 견인하고 있습니다. 그러나 첨단 치료법에 따른 높은 비용과 개발도상국에서의 낮은 인지도가 시장 성장을 저해하는 요인으로 작용하고 있습니다. 유전자 치료 기반 치료법의 채택 확대는 시장 관계자들에게 큰 기회를 제공합니다. 저렴한 재생의료 옵션의 개발도 가까운 미래에 새로운 길을 열 수 있는 잠재력을 가지고 있습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계 겸상 적혈구 증후군 치료제 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계 겸상 적혈구 증후군 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 겸상 적혈구 증후군 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 겸상 적혈구 증후군 치료 시장 : 치료 유형별, 2021년-2033년
제5장 세계의 겸상 적혈구 증후군 치료 시장 : 연령층별, 2021년-2033년
제6장 세계의 겸상 적혈구 증후군 치료 시장 : 투여 경로별, 2021년-2033년
제7장 세계의 겸상 적혈구 증후군 치료 시장 : 최종사용자별, 2021년-2033년
제8장 세계의 겸상 적혈구 증후군 치료 시장 : 유통 채널별, 2021년-2033년
제9장 세계의 겸상 적혈구 증후군 치료 시장 : 지역별, 2021년-2033년
제10장 경쟁 구도
제11장 애널리스트의 제안
제12장 참고 문헌 및 조사 방법
LSH 26.06.15Sickle Cell Disease Treatment Market is estimated to be valued at USD 3.70 Bn in 2026 and is expected to reach USD 10.35 Bn by 2033, growing at a compound annual growth rate (CAGR) of 15.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.70 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 15.80% | 2033 Value Projection: | USD 10.35 Bn |
Sickle cell disease is a genetic blood disorder causing abnormal red blood cells. It affects the oxygen supply to tissues and organs in the body. This disorder is prevalent across worldwide, especially in Sub-Saharan Africa, the Middle East, Indian subcontinent, Mediterranean regions, and South and Central America. With growing diagnostic and detection rates, coupled with rising awareness regarding availability of advanced treatment options, the market is projected to showcase lucrative opportunities over the coming years. The development of new drug therapies and gene-therapy based treatment approaches are also fueling the market expansion.
Market Dynamics
Increasing research activities focusing on developing novel drugs and upcoming pipeline candidates are acting as a key growth driver for global sickle cell disease treatment market. Rising healthcare expenditures in emerging nations and favorable reimbursement policies are further supporting the market growth. Growing adoption of curative therapies such as bone marrow transplantation is also boosting the market. However, high costs associated with advanced treatment approaches and lack of awareness in underdeveloped regions are restraining the market growth. Rising adoption of gene-therapy based treatments presents significant opportunities for market players. Development of affordable regenerative treatment options also holds potential to create new avenues in the near future.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global sickle cell disease treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, Emmaus Medical Inc., Agios Pharmaceuticals Inc., Bluebird Bio, Pfizer Inc., Bristol-Myers Squibb Company, Celgene Corporation, GSK (GlaxoSmithKline), Sanofi S.A., Merck & Co., Inc., Amgen Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Company, Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global sickle cell disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sickle cell disease treatment market
Market Segmentation
- By Treatment Type Insights (Revenue, USD Bn, 2021 - 2033)
- Blood Transfusion
- Bone Marrow Transplant
- Pharmacotherapy
- Hydroxyurea Therapy
- Oxbryta
- Adakveo
- Pain Management Drugs
- Others
- By Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Adults
- Pediatric
- Geriatric
- By Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- By End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
- By Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis AG
- Emmaus Medical Inc.
- Agios Pharmaceuticals Inc.
- Bluebird Bio
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Celgene Corporation
- GSK (GlaxoSmithKline)
- Sanofi S.A.
- Merck & Co., Inc.
- Amgen Inc.
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Chugai Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company, Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Sickle Cell Disease Treatment Market, By Treatment Type
- Global Sickle Cell Disease Treatment Market, By Age Group
- Global Sickle Cell Disease Treatment Market, By Route of Administration
- Global Sickle Cell Disease Treatment Market, By End User
- Global Sickle Cell Disease Treatment Market, By Distribution Channel
- Global Sickle Cell Disease Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Sickle Cell Disease Treatment Market, By Treatment Type, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Blood Transfusion
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Bone Marrow Transplant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Pharmacotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Hydroxyurea Therapy
- Oxbryta
- Adakveo
- Pain Management Drugs
- Others
5. Global Sickle Cell Disease Treatment Market, By Age Group, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
6. Global Sickle Cell Disease Treatment Market, By Route of Administration, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
7. Global Sickle Cell Disease Treatment Market, By End User, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
8. Global Sickle Cell Disease Treatment Market, By Distribution Channel, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
9. Global Sickle Cell Disease Treatment Market, By Region, 2021 - 2033, Value (USD Billion)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Billion)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Billion)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Billion)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Billion)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Billion)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Billion)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Billion)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Billion)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Emmaus Medical Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Agios Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bluebird Bio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celgene Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK (GlaxoSmithKline)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Chugai Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo Company, Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
